BACKGROUND: Daily co-trimoxazole is recommended for African adults living with human immunodeficiency virus (HIV) irrespective of antiretroviral treatment, immune status, or disease stage. Benefits of continued prophylaxis and whether co-trimoxazole can be stopped following immune reconstitution are unknown. METHODS: We conducted a randomized controlled trial at 2 sites in Malawi that enrolled adults with HIV with undetectable viral load and CD4 count of >250/mm3 and randomized them to continue daily co-trimoxazole, discontinue daily co-trimoxazole and begin weekly chloroquine, or discontinue daily co-trimoxazole. The primary endpoint was the preventive effect of co-trimoxazole prophylaxis against death or World Health Organization (WHO) HIV/AIDS stage 3-4 events, using Cox proportional hazards modeling, in an intention-to-treat population. RESULTS: 1499 adults were enrolled. The preventive effect of co-trimoxazole on the primary endpoint was 22% (95% CI: -14%-47%; P = .20) versus no prophylaxis and 25% (-10%-48%; P = .14) versus chloroquine. When WHO HIV/AIDS stage 2 events were added to the primary endpoint, preventive effect increased to 31% (3-51%; P = .032) and 32% (4-51%; P = .026), respectively. Co-trimoxazole and chloroquine prophylaxis effectively prevented clinical malaria episodes (3.8 and 3.0, respectively, vs 28/100 person-years; P < .001). CONCLUSIONS: Malawian adults with HIV who immune reconstituted on ART and continued co-trimoxazole prophylaxis experienced fewer deaths and WHO HIV/AIDS stage 3-4 events compared with prophylaxis discontinuation, although statistical significance was not achieved. Co-trimoxazole prevented a composite of death plus WHO HIV/AIDS stage 2-4 events. Given poor healthcare access and lack of routine viral load monitoring, co-trimoxazole prophylaxis should continue in adults on ART after immune reconstitution in sub-Saharan Africa. Clinical Trials Registration. NCT01650558.
BACKGROUND: Daily co-trimoxazole is recommended for African adults living with human immunodeficiency virus (HIV) irrespective of antiretroviral treatment, immune status, or disease stage. Benefits of continued prophylaxis and whether co-trimoxazole can be stopped following immune reconstitution are unknown. METHODS: We conducted a randomized controlled trial at 2 sites in Malawi that enrolled adults with HIV with undetectable viral load and CD4 count of >250/mm3 and randomized them to continue daily co-trimoxazole, discontinue daily co-trimoxazole and begin weekly chloroquine, or discontinue daily co-trimoxazole. The primary endpoint was the preventive effect of co-trimoxazole prophylaxis against death or World Health Organization (WHO) HIV/AIDS stage 3-4 events, using Cox proportional hazards modeling, in an intention-to-treat population. RESULTS: 1499 adults were enrolled. The preventive effect of co-trimoxazole on the primary endpoint was 22% (95% CI: -14%-47%; P = .20) versus no prophylaxis and 25% (-10%-48%; P = .14) versus chloroquine. When WHO HIV/AIDS stage 2 events were added to the primary endpoint, preventive effect increased to 31% (3-51%; P = .032) and 32% (4-51%; P = .026), respectively. Co-trimoxazole and chloroquine prophylaxis effectively prevented clinical malaria episodes (3.8 and 3.0, respectively, vs 28/100 person-years; P < .001). CONCLUSIONS: Malawian adults with HIV who immune reconstituted on ART and continued co-trimoxazole prophylaxis experienced fewer deaths and WHO HIV/AIDS stage 3-4 events compared with prophylaxis discontinuation, although statistical significance was not achieved. Co-trimoxazole prevented a composite of death plus WHO HIV/AIDS stage 2-4 events. Given poor healthcare access and lack of routine viral load monitoring, co-trimoxazole prophylaxis should continue in adults on ART after immune reconstitution in sub-Saharan Africa. Clinical Trials Registration. NCT01650558.
Authors: James D Campbell; David Moore; Richard Degerman; Frank Kaharuza; Willy Were; Emmy Muramuzi; George Odongo; Milton Wetaka; Jonathan Mermin; Jordan W Tappero Journal: Clin Infect Dis Date: 2012-03-14 Impact factor: 9.079
Authors: X Anglaret; G Chêne; A Attia; S Toure; S Lafont; P Combe; K Manlan; T N'Dri-Yoman; R Salamon Journal: Lancet Date: 1999-05-01 Impact factor: 79.321
Authors: C Chintu; G J Bhat; A S Walker; V Mulenga; F Sinyinza; K Lishimpi; L Farrelly; N Kaganson; A Zumla; S H Gillespie; A J Nunn; D M Gibb Journal: Lancet Date: 2004 Nov 20-26 Impact factor: 79.321
Authors: Jonathan Mermin; John Lule; John Paul Ekwaru; Samuel Malamba; Robert Downing; Ray Ransom; Frank Kaharuza; David Culver; Francis Kizito; Rebecca Bunnell; Aminah Kigozi; Damalie Nakanjako; Winnie Wafula; Robert Quick Journal: Lancet Date: 2004 Oct 16-22 Impact factor: 79.321
Authors: A S Walker; D Ford; C F Gilks; P Munderi; F Ssali; A Reid; E Katabira; H Grosskurth; P Mugyenyi; J Hakim; J H Darbyshire; D M Gibb; A G Babiker Journal: Lancet Date: 2010-03-27 Impact factor: 79.321
Authors: Diana M Gibb; A Sarah Walker; Andrew J Prendergast; Mutsawashe Bwakura-Dangarembizi; Lindsay Kendall; Sabrina Bakeera-Kitaka; Patricia Nahirya-Ntege; Rosette Keishanyu; Kusum Nathoo; Moira J Spyer; Adeodata Kekitiinwa; Joseph Lutaakome; Tawanda Mhute; Philip Kasirye; Paula Munderi; Victor Musiime Journal: N Engl J Med Date: 2014-01-02 Impact factor: 91.245
Authors: Mia Liisa van der Kop; Lehana Thabane; Patricia Opondo Awiti; Samuel Muhula; Lennie Bazira Kyomuhangi; Richard Todd Lester; Anna Mia Ekström Journal: BMC Infect Dis Date: 2016-04-18 Impact factor: 3.090
Authors: Christina S Polyak; Krista Yuhas; Benson Singa; Monica Khaemba; Judd Walson; Barbra A Richardson; Grace John-Stewart Journal: PLoS Med Date: 2016-01-05 Impact factor: 11.069
Authors: Randy G Mungwira; Matthew B Laurens; Wongani Nyangulu; Titus H Divala; Nginache Nampota-Nkomba; Andrea G Buchwald; Osward M Nyirenda; Edson Mwinjiwa; Maxwell Kanjala; Lufina Tsirizani Galileya; Dominique E Earland; Matthew Adams; Christopher V Plowe; Terrie E Taylor; Jane Mallewa; Joep J van Oosterhout; Miriam K Laufer Journal: AIDS Date: 2022-07-15 Impact factor: 4.632
Authors: Kirsten Alexandra Eberhardt; Fred Stephen Sarfo; Eva-Maria Klupp; Albert Dompreh; Veronica Di Cristanziano; Edmund Osei Kuffour; Richard Boateng; Betty Norman; Richard Odame Phillips; Martin Aepfelbacher; Torsten Feldt Journal: Microorganisms Date: 2021-08-22
Authors: Lufina Tsirizani-Galileya; Elasma Milanzi; Randy Mungwira; Titus Divala; Jane Mallewa; Donnie Mategula; Nginache Nampota; Victor Mwapasa; Andrea Buchwald; Matthew B Laurens; Miriam K Laufer; Joep J Van Oosterhout Journal: Medicine (Baltimore) Date: 2022-09-30 Impact factor: 1.817